Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Targeted Therapies in Head and Neck Cancer: Past, Present and Future
复制标题
DOI：
10.2174/157488708785700285
复制
发表时间：
2008-01-01
影响因子：
1.9
通讯作者：
Bourhis, Jean
中科院分区：
文献类型：
--
作者：
Rapidis, Alexander D.;Vermorken, Jan B.;Bourhis, Jean
头颈部癌症仍然是全球范围内的一个重大健康问题。局部进展性头颈部鳞状细胞癌(SCCHN)在放射治疗的基础上加用化疗，可以改善局部疾病的控制和生存率，但也伴随着严重的急性和晚期毒性反应。在复发和/或转移性SCCHN中，尽管采用了标准的治疗方案并引入了新的细胞毒药，但生存率并没有改善。在过去的十年里，靶向治疗越来越多地被用于一系列实体肿瘤类型。本文讨论了一些靶向药物在局部晚期和复发和/或转移性SCCHN治疗中的临床证据。本文重点介绍了表皮生长因子受体(EGFR)抑制剂，这些药物的大部分临床信息都是可用的。这些药物包括单抗(MAb)西妥昔单抗和酪氨酸激酶抑制剂厄洛替尼和吉非替尼。还提供了血管内皮生长因子(VEGF)抑制剂贝伐单抗的临床数据。
Head and neck cancers remain a significant health problem globally. The addition of chemotherapy to radiotherapy for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) has led to improvements in locoregional disease control and in survival, but is associated with substantial acute and late toxicities. In recurrent and/or metastatic SCCHN, there have been no improvements in survival, despite the manipulation of standard therapeutic regimens and the introduction of newer cytotoxic agents. Over the last decade, targeted therapies have been increasingly used in a range of solid tumor types. This article discusses the clinical evidence for the use of a number of targeted agents in the treatment of locoregionally advanced and recurrent and/or metastatic SCCHN. The article focuses on the epidermal growth factor receptor (EGFR) inhibitors, for which the majority of clinical information is available. These include the monoclonal antibody (MAb) cetuximab and the tyrosine kinase inhibitors, erlotinib and gefitinib. Clinical data for the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, are also presented.